Literature DB >> 25246081

Tracking the origin of metastatic prostate cancer.

Johan Lindberg1, Anna Kristiansen2, Peter Wiklund3, Henrik Grönberg4, Lars Egevad5.   

Abstract

UNLABELLED: Metastatic prostate cancer is a monoclonal disease. We previously failed to identify a common somatic denominator between primary tumor tissue and two lymph-node metastases by exome sequencing [Lindberg J, et al. Eur Urol 2013;63:702-8]. To track the seeding clone we performed copy-number alteration analysis on 34 morphologically distinct tissue areas in one prostatectomy specimen. Using break-point regions to infer phylogenetic relationships, the clone most closely related to the metastases was found in intraductal carcinoma of the prostate. Although the majority of tumor areas harbored events also found in the metastases, three carried none. This emphasizes the importance of intraprostatic tumor heterogeneity for prediction of prognosis. These findings also support recent evidence that intraductal carcinoma is a marker of aggressive disease. PATIENT
SUMMARY: We identified the area in the prostate that gave rise to metastases by searching for metastatic-specific DNA alterations in multiple regions of the prostate. The metastasizing component grew within prostatic ducts, suggesting that intraductal cancer should be reported when found in needle biopsies. It is also important to be aware of tumor heterogeneity when assessing somatic changes linked to tumor aggressiveness.
Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heterogeneity; Intraductal carcinoma; Metastasis; Prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 25246081     DOI: 10.1016/j.eururo.2014.09.006

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  27 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  Intraductal carcinoma of prostate (IDC-P): from obscure to significant.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

3.  Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.

Authors:  Akiyuki Yamamoto; Masashi Kato; Hirotaka Matsui; Ryo Ishida; Tohru Kimura; Yasuhito Funahashi; Naoto Sassa; Yoshihisa Matsukawa; Osamu Kamihira; Ryohei Hattori; Momokazu Gotoh; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2018-02-03       Impact factor: 3.402

4.  The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation.

Authors:  Masashi Kato; Toyonori Tsuzuki; Kyosuke Kimura; Akihiro Hirakawa; Fumie Kinoshita; Naoto Sassa; Ryo Ishida; Akitoshi Fukatsu; Tohru Kimura; Yasuhito Funahashi; Yoshihisa Matsukawa; Ryohei Hattori; Momokazu Gotoh
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

5.  Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.

Authors:  Michael C Haffner; Christopher Weier; Meng Meng Xu; Ajay Vaghasia; Bora Gürel; Berrak Gümüşkaya; David M Esopi; Helen Fedor; Hsueh-Li Tan; Ibrahim Kulac; Jessica Hicks; William B Isaacs; Tamara L Lotan; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  J Pathol       Date:  2015-10-14       Impact factor: 7.996

6.  Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

Authors:  Charlotte F Kweldam; Intan P Kümmerlin; Daan Nieboer; Esther I Verhoef; Ewout W Steyerberg; Theodorus H van der Kwast; Monique J Roobol; Geert J van Leenders
Journal:  Mod Pathol       Date:  2016-03-04       Impact factor: 7.842

7.  Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens.

Authors:  Beatrice S Knudsen; Hyung L Kim; Nicholas Erho; Heesun Shin; Mohammed Alshalalfa; Lucia L C Lam; Imelda Tenggara; Karen Chadwich; Theo Van Der Kwast; Neil Fleshner; Elai Davicioni; Peter R Carroll; Matthew R Cooperberg; June M Chan; Jeffry P Simko
Journal:  J Mol Diagn       Date:  2016-03-03       Impact factor: 5.568

8.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

Review 9.  The Genomics of Prostate Cancer: A Historic Perspective.

Authors:  Mark A Rubin; Francesca Demichelis
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

10.  Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer.

Authors:  Masashi Kato; Akihiro Hirakawa; Yumiko Kobayashi; Akiyuki Yamamoto; Yushi Naito; Kosuke Tochigi; Tomoyasu Sano; Shohei Ishida; Yasuhito Funahashi; Takashi Fujita; Yoshihisa Matsukawa; Ryohei Hattori; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2020-08-03       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.